Proposal for the use of an inhalation drug containing 2-5 oligoadenylates for treatment of COVID-19

Interferons (IFN), first described 1957 by Isaacs and Lindemann, are antiviral proteins generated in cells after viral infections. One of several interferon-induced effector mechanisms is the so called 2-5A / RNaseL system: Interferon is produced in the virus-affected cells and released. After bindi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruchelt, Gernot, Treuner, Jörn, Schmidt, Karlheinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605919/
https://www.ncbi.nlm.nih.gov/pubmed/36317071
http://dx.doi.org/10.1016/j.mehy.2022.110969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605919/
https://www.ncbi.nlm.nih.gov/pubmed/36317071
http://dx.doi.org/10.1016/j.mehy.2022.110969

Ejemplares similares